Skip to main content

Recognizing and managing sepsis: what needs to be done?


Sepsis is associated with significant morbidity and mortality if not promptly recognized and treated. Since the development of early goal-directed therapy, mortality rates have decreased, but sepsis remains a major cause of death in patients arriving at the emergency department or staying in hospital. In this forum article, we asked clinicians and researchers with expertise in sepsis care to discuss the importance of rapid detection and treatment of the condition, as well as special considerations in different patient groups.

The key role of early care in sepsis

Donald M. Yealy (Figure 1) and David T. Huang (Figure 2)

Figure 1
figure 1

Donald M. Yealy, MD, is Professor and Chair of Emergency Medicine at the University of Pittsburgh and University of Pittsburgh Medical Center. He has focused on clinical decision-making and the early care of many life-threatening conditions, including community-acquired pneumonia, sepsis, acute heart failure, and respiratory failure. He has over 300 scientific publications and was awarded the highest recognitions from the American College of Emergency Physicians and the Society for Academic Emergency Medicine for his research, teaching, and leadership.

Figure 2
figure 2

David T. Huang, MD, MPH, has focused on biomarkers and resuscitation of infection and sepsis, early treatment of acute respiratory distress syndrome, and emergency medicine-critical care medicine physician demographics and education. He is a Fellow of the American College of Emergency Physicians and the American College of Critical Care Medicine, and Director of MACRO (Multidisciplinary Acute Care Research Organization) at the University of Pittsburgh.

Figure 3
figure 3

Anthony Delaney, MBBS, MSc, PhD, FACEM, FCICM, is a Fellow of the Australasian College for Emergency Medicine and the College of Intensive Care Medicine. He is a Senior Staff Specialist in the Malcolm Fisher Department of Intensive Care Medicine at Royal North Shore Hospital, a Senior Lecturer at Sydney Medical School, University of Sydney, and an adjunct Senior Research Fellow at the Australian and New Zealand Intensive Care Research Centre, in the Department of Epidemiology and Preventative Health at Monash University.

Figure 4
figure 4

Marian Knight is Professor of Maternal and Child Population Health, NIHR Research Professor and Honorary Consultant in Public Health at the National Perinatal Epidemiology Unit, University of Oxford. Her research interests include severe maternal morbidity and the use of population-based observational studies to address key clinical questions in obstetrics. Since 2012, she has led the UK Confidential Enquiries into Maternal Deaths and Morbidity, which most recently focused on maternal sepsis.

Figure 5
figure 5

Adrienne Randolph is a Senior Associate in Critical Care at Boston Children’s Hospital and a Professor of Anesthesia at Harvard Medical School. She founded the Pediatric Acute Lung Injury and Sepsis Investigator’s (PALISI) Network, a voluntary network of over 80 large pediatric centers across the US and Canada. This network has performed numerous observational studies and clinical trials in children with severe infections. She currently directs Pediatric Intensive Care Influenza and Emerging Severe Pathogens (PICLFU-ESP), a network of investigators with studies funded by the NIH and CDC.

Figure 6
figure 6

Ron Daniels is a Consultant in Critical Care based in the United Kingdom (Birmingham). He is CEO of the UK Sepsis Trust and Global Sepsis Alliance, and Clinical Adviser on Sepsis to NHS England.

Figure 7
figure 7

Tim Nutbeam is a consultant emergency physician and clinical academic based in the United Kingdom (Plymouth). He is clinical project lead for the UK Sepsis Trust.

Described for centuries, sepsis is a maladaptive inflammatory response to infection, creating profound symptoms and poor outcomes, including high short-term mortality [1,2]. Even into the late 1990s, our experiences, expectations, and insight into the care of the septic patient were dismal and grim. We knew that inflammatory mediators, coagulation, cellular oxygen processing, and both macro- and micro-circulation could be disturbed; the cascading interaction(s) created the dismal outcomes that we dutifully reported and lamented. Half or more of those afflicted died during hospitalization, and we intervened after organ failure was clear using promising biologics that seemed to fix some facets but did not improve mortality or function after recovery.

In 2001, Rivers et al. [3] explored a newer approach, termed Early Goal-Directed Therapy (EGDT). The conceptual model of EGDT was that sepsis and, in some instances, septic shock are under-recognized and hence under-treated. Rather than target mediators and individual organ or cellular events, Rivers et al. [3] sought to limit the global oxygen deficits accompanying sepsis to thwart the cycle of ‘evil humors running amok’ and creating dysfunction. EGDT attempted to achieve this by guiding the first 6 hours of resuscitation with central venous pressure and saturation measures. The structured EGDT approach delivered more fluids (5 L mean) in the first 6 hours, more inotropic support, and more frequent red blood cell transfusion than an unstructured approach. This EGDT use translated into a 16% absolute mortality benefit compared to controls, the most stark noted in sepsis care. Based on this, many called for central catheter-driven EGDT care for all with septic shock [4].

Follow-up work replicated the general observation that earlier recognition, coupled with resuscitative care, improved outcomes [5]. Often, the sites involved had little pre-existing focus on sepsis recognition and care; even when the full EGDT protocol was not implemented – a common event – outcomes improved, suggesting that one path to improved care was possible.

At the same time, others noted a parallel opportunity with another sepsis care target – source control with antibiotics. Delays in delivering appropriate antibiotics led to higher mortality, akin to delayed resuscitation [6]. Coupling these therapeutic insights with the observation that much of the hospitalized sepsis population receives initial care in the emergency department reinforced the importance of early care [7].

Recent research helped clarify the key messages of what early care should be. Jones et al. [8] demonstrated that early resuscitation in the first 6 hours after an aggressive search for sepsis/septic shock using bedside information and serial lactate measurements (to aid resuscitation assessment) was non-inferior to the more regimented and resource-intensive EGDT approach suggested by Rivers et al. [3], delivering hospital mortality rates of 17 to 23%. Our ProCESS trial examined 1,351 patients in 30 US sites, assessing three approaches to resuscitation after early recognition and antibiotic therapy: EGDT with the mandated central oximetric catheter guiding care; a simpler but team-based and clinically-driven protocol; or bedside care tailored by the treating physician (usual care) [9]. The groups received a mean of 4.3 to 5.3 L of fluids through hour 6 of resuscitation and varying amounts of pressor, blood, and inotrope use. Despite the aggressive but varying approaches between those treated in each arm, we observed that how fluids and vasoactive agents were provided did not create a superior outcome as long as each was done early, aggressively, and in the backdrop of early antibiotic use. The 60-d hospital mortality amongst the three arms ranged from 18 to 21%, and the secondary outcomes, including organ support and longer term recovery, also did not differ. The ARISE trial, based in Australia/New Zealand, also studied EGDT compared to usual, unstructured care in 1,600 patients with early recognition and infection source control [10]. Like ProCESS, the two different methods of resuscitation in ARISE did not identify one as better and the overall outcomes were improved compared to a decade prior. A separate national surveillance study from Australia/New Zealand confirmed that these lower hospital mortality rates are not simply research or coding aberrations and are due, in part, to earlier care efforts [11].

Where are we at?

Despite advances, sepsis remains one of the most deadly emergency department arrival or hospital-acquired conditions. Initial sepsis care remains uneven and often sluggish [12]. Long term outcomes show an accrual of death at 1 year after a bout of septic shock exceeding 50% [13] and frequent functional impairment in survivors [14]. While awaiting newer tools to aid detection or treat those who do not respond, we need to focus on wider use of “egdt” – early and simple detection coupled with the goals of fluids that are adequate and directed by bedside reassessment and appropriate antibiotic therapy – rather than any one singular prescriptive form of resuscitation. Early care matters – not so much a mandated catheter or prescriptive approach – and returning to the days of delayed action is not an option.

Competing interests

No current industry support in this area. DMY and DTH are funded by NHLBI for the Prevention and Early Treatment of Acute Lung Injury Network (PETAL) and by NIGMS for the Procalcitonin Antibiotic Consensus Trial (ProACT).

How can we improve the recognition of sepsis?

Anthony Delaney (Figure 3)

Sepsis remains a leading cause of mortality worldwide. While there has been a measureable reduction in mortality over recent years [11], the underlying reasons for this decline in mortality are not entirely clear. More than 100 trials of specific treatments designed to improve mortality in sepsis have failed to demonstrate a mortality benefit [15]. It is possible that further research will lead to a discovery of a novel agent capable of altering the complex interaction between the specific pathogenic mechanisms of various infective agents, the generic host inflammatory reaction to infection, and the pathophysiological response mediated by each individuals’ co-morbidities, in a positive fashion, although such a therapy would appear remote from clinical practice at this point in time. As described in the previous section, the EGDT resuscitation strategy [3] changed the landscape in the management of the early stages of patients with severe sepsis and septic shock. Although subsequent trials [9,10] have not confirmed the benefits of this specific resuscitation algorithm, it is considered that early recognition of sepsis and early application of the fundamental principles of the treatment of sepsis, namely resuscitation, antibiotics, and source control, may have contributed to the gradual decline in mortality over recent times. One of the major challenges facing clinicians is to identify and recognize patients with sepsis and impending organ dysfunction, in the pre-hospital setting, in the emergency department, and for patients who deteriorate in hospital.

Attention to the pre-hospital phase in patients with sepsis is clearly critical. The initial link in this chain is to increase awareness of the symptoms of sepsis amongst the general public. Organizations such as the Global Sepsis Alliance and initiatives like World Sepsis Day, which work to raise awareness of sepsis, play a crucial role in alerting the general public about the importance of seeking medical attention when they or a loved one displays the symptoms of sepsis. Pre-hospital care also plays an important role in recognizing and providing prompt care for patients with sepsis. Approximately 50% of the patients who present to the emergency department with sepsis will arrive via an Emergency Medical Service (EMS) [16]. This exposure provides an excellent opportunity to improve early recognition of sepsis and to commence an integrated system of care for these complex patients. For example, in a pilot prospective cohort study conducted in the pre-hospital setting, early identification of patients with severe sepsis by EMS providers utilizing a screening tool and a point-of-care venous lactate meter was shown to be feasible [17]. Once identified, there is scope for interventions, such as intravenous cannulation and initiation of intravenous fluids provided pre-hospital, to influence the outcomes of patients with sepsis [18].

An enhanced focus on the identification of sepsis in the emergency department setting, as recommended by the Surviving Sepsis Campaign Guidelines [4], has been shown in numerous studies to be associated with improved outcomes [19]. Identifying patients with sepsis in a busy emergency department may be aided by the use of electronic sepsis alert systems [20], or a screening tool that combines simple clinical characteristics with the use of early lactate measurements [21]. Simple tools have been combined in successful large-scale quality improvement programs, such as the Sepsis Kills campaign, run by the Clinical Excellence Commission in NSW, Australia [22], and the Surviving Sepsis Campaign [23]. It is very likely that the increased focus on sepsis by clinical champions, and the awareness amongst front line staff regarding the possibility of sepsis that accompanies such campaigns, is responsible for much of the improved outcomes demonstrated in these programs.

Identifying patients who deteriorate within the hospital secondary to sepsis presents an additional challenge. These populations often have concurrent medical or surgical conditions that confound the diagnosis, making early recognition difficult. The widespread introduction of rapid response systems has led to the early identification and the initiation of early intervention to patients within the hospital system [24], many of whom will deteriorate secondary to sepsis. One other area that offers ongoing promise with regards to the early identification of patients with sepsis is the use of biomarkers. These may be applicable to patients in the emergency department and within the hospital. Traditional individual markers of sepsis, such as the total white cell count, neutrophil count, and C-reactive protein, lack the specificity to allow them to discriminate between those patients with an inflammatory response to trauma or surgery, for example, and those with a new infection. The best studied of the newer biomarkers of sepsis, procalcitonin, which has been investigated in more than 3,000 patients suspected of sepsis [25], does not have sufficient sensitivity to identify all cases of sepsis reliably, nor the specificity to rule out sepsis when negative. Other tests, such as the soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), offer some promise, but still have inadequate sensitivity and specificity to be used as a single biomarker for sepsis. Panels of biomarkers, including sTREM-1, procalcitonin, CD 64 expression on neutrophils, and C-reactive protein, as well as other novel biomarkers, offers some promise as diagnostic markers of sepsis yet to be confirmed in large scale clinical trials [26]. Table 1 summarizes the sensitivity and specificity of selected biomarkers for sepsis.

Table 1 Sensitivity and specificity of selected biomarkers for the diagnosis of sepsis

There are still challenges to be overcome with regards to improving the early recognition of sepsis. The current definition of sepsis [4] remains overly complex and difficult to use in a clinical setting. A new definition, incorporating simple clinical measures, may greatly enhance the evolving clinical science as well as the clinical practice of diagnosing early sepsis. Identifying the best sepsis screening tools, and refining a biomarker or set of biomarkers to definitively identify patients who have sepsis, is a major challenge. These challenges need to be addressed so that, in populations with altered physiology, such as women who are pregnant or in the early post-partum, period, or those in whom clinical features may be non-specific, such as infants and children, the diagnosis of sepsis can be made and the important early interventions can be commenced in an expedient fashion.

Competing interests

The author was an investigator for the Australasian Resuscitation in Sepsis Evaluation study, a multi-center randomised trial of Early Goal-Directed Therapy, funded by the Australian National Health and Medical Research Council.

Sepsis in pregnancy and the postpartum period

Marian Knight (Figure 4)

Sepsis is an important cause of both morbidity and mortality in pregnancy and the postpartum period; approximately one in every thousand women giving birth will develop sepsis, with half of these women progressing to severe sepsis and 3 to 4% developing septic shock [27]. Maternal sepsis is a challenge in both low- and high-resource settings; one-quarter of women who die within the 6 weeks after pregnancy in the UK die from sepsis [28]. Globally, an estimated 11% of maternal deaths are caused by sepsis, the vast majority occurring in developing regions [29].

There are several well-recognized risk factors for maternal sepsis, including the presence of pre-existing medical conditions such as anemia, febrile illness in the 2 weeks prior to diagnosis of sepsis, and, most notably, mode of delivery [30]. Cesarean delivery and operative vaginal delivery are both associated with severe maternal sepsis [31]. The predominant causes of maternal sepsis vary according to the timing of infection; antenatally, infections of the urinary tract make up about one-third of all cases of maternal sepsis, whereas postnatally, one-third of sepsis is due to genital tract infections [31]. Overall, infections due to E. coli are most numerous, but infections with Group A Streptococcus are significantly associated with greater severity of sepsis [31]. There is good evidence that pregnant women are at higher risk of complications of certain specific infections, for example, influenza, varicella zoster, and listeria.

Pregnant and postpartum women are, in general, young and fit and compensate well, even in the presence of severe infection [32]. Infection may thus be well established before a diagnosis of sepsis is made. Early consideration of the diagnosis and, hence, early recognition is therefore perhaps even more critical in the obstetric population. This is dependent on both the measurement of vital signs in any unwell pregnant or postpartum woman, as well as acting on the findings [28]. Although pregnancy and childbirth is a normal physiological process, normality cannot be assumed in the presence of abnormal signs or symptoms. It is important to note that symptoms, such as severe abdominal pain, breathlessness, and diarrhea, may be associated with postpartum sepsis. Additionally, maternal sepsis should always be considered as part of the differential diagnosis in a postpartum woman presenting with shock. Although hemorrhage is the commonest cause of shock in a postpartum woman, possible sepsis must be investigated, particularly if blood loss is only moderate and treatment for hemorrhage appears ineffective.

In relation to maternal shock, it is important to be aware of the significance of Group A Streptococcal infection. Although cesarean delivery and operative vaginal delivery are both risk factors for maternal sepsis, Group A Streptococcal infections are proportionately more frequently seen in women who have had an unassisted vaginal delivery. Group A Streptococcal infection is a known risk factor for development of septic shock, and is associated with rapid sepsis progression [31]. In a UK national study of severe maternal sepsis, for 75% of women with a Group A Streptococcal infection there was less than 9 hours between the first signs of systemic inflammatory response syndrome and the diagnosis of severe sepsis [31]. In 50% of women this was less than 2 hours.

As with sepsis in general populations, along with early recognition and diagnosis, the key action for management is to institute a sepsis care bundle, including administration of timely antibiotics (within 1 hour of suspected sepsis), adequate fluid resuscitation, and the measurement of serum lactate [28]. There is no specific sepsis care bundle suggested for use in pregnancy or the postpartum period; several have been recommended, including the Surviving Sepsis Campaign resuscitation care bundles [4], the Institute for Healthcare Improvement severe sepsis bundles [33], and the ‘Sepsis Six Care Bundle’ from the UK Sepsis Trust [34]. The choice of antibiotic is dependent on the likely source of infection, taking into account known hospital and individual factors such as prevalence of antibiotic resistant organisms and mode of delivery. Adjustment may be made later based on the woman’s response and subsequent culture results.

Source control is essential in the timely management of maternal sepsis; bearing in mind that this may require cesarean delivery, hysterotomy, or hysterectomy in women with genital tract sepsis. The UK and Ireland Confidential Enquiry into Maternal Deaths identified a number of women who subsequently died from maternal sepsis following delayed delivery [28]. In several women, delivery was delayed because the fetus had already died and there was a perceived need to ensure the woman delivered vaginally. Failure to deliver the fetus and placenta early in this situation will lead to a persisting source of infection and progression of the woman’s sepsis despite adequate resuscitation and antibiotic treatment.

Some evidence suggests that rates of maternal sepsis may be increasing [27], and with more than an estimated 30,000 maternal deaths from sepsis annually [29], ongoing awareness of the diagnosis, timely recognition, and management is vital.

Competing interests

The author declares that she has no competing interests.

Recognizing and managing pediatric sepsis

Adrienne G. Randolph (Figure 5)

Overwhelming infection is the major cause of death in children worldwide [35]. Neonates and young infants are at highest risk because their immature immune systems are less able to ward off severe pathogens [35,36]. Sepsis – when a patient has a systemic inflammatory response to a suspected or confirmed infection [37] – is a useful construct in that it should bring the clinician to the bedside to examine the child and determine the proper treatment course. Children who develop signs of severe sepsis with organ dysfunction, and especially those who develop septic shock, are at highest risk of life-threatening and fatal complications. In recent years, the approach to treating septic shock in the pediatric patient has focused on early recognition of severe sepsis. This is followed by rapid treatment with antibiotics and aggressive treatment of shock with fluid boluses and, if refractory, with vasoactive agents. These interventions, extrapolated from the care of septic adults, have been widely disseminated as clinical guidelines [4]. Implementation of these interventions as care bundles with audit and feedback can optimize clinician compliance [38]. Although no large multi-center randomized trials have been performed, there is some evidence that implementation of early sepsis recognition, prompt delivery of antibiotics, and intravenous fluids have improved clinical outcomes [4]. There is very strong evidence that focused attention on constantly adhering to the use of central-line insertion and maintenance bundles can prevent nosocomial sepsis from central line-associated bloodstream infections [39].

Early sepsis recognition and aggressive treatment are necessary but insufficient. Treatment of ‘sepsis’ should rapidly evolve into a specific diagnosis with targeted antimicrobial therapy against the bacterial, viral, fungal or protozoal invading pathogen. The most common infection in children is pneumonia, the majority caused by viral pathogens [40]. Therefore, despite their widespread use, antibiotics are ineffective for most children with a severe infection. With the exception of influenza, antivirals are also usually not indicated in immune competent hosts. The rapid implementation of strategies aimed at decreasing use of antibiotics is also not without risk. Children with life-threatening viral infections are frequently co-infected with highly pathogenic bacteria. In recent years, methicillin-resistant Staphylococcal aureus or MRSA, which used to be relatively rare in children, has taken a rising toll; influenza-MRSA is an especially fatal combination [41].

Although pediatric sepsis is common, no large-scale epidemiologic study has been performed to refine the widely used pediatric sepsis diagnostic criteria [37]. These criteria were originally developed for identifying children eligible to participate in a drug trial and not for clinical management. Tachypnea, tachycardia, fever, and alterations in leucocyte count are sensitive indicators, but they encompass many non-infectious acute inflammatory disorders. Delayed capillary refill, lethargy, and other signs of severe sepsis are also highly relevant but non-specific. Which children should be given fluid, what type of fluid, and how much, are all areas that merit urgent study. A recent study of aggressive fluid resuscitation in African children with compensated shock revealed worse outcomes in those who received fluid boluses with albumin or saline [42], a surprising finding that was difficult to understand. Whether aggressive fluid resuscitation in children with bronchiolitis or pneumonia that present with poor capillary refill and other signs of compensated shock improves or worsens their outcome is yet to be evaluated.

Rigorous implementation of the Surviving Sepsis guidelines will save many lives, but the broad definition of sepsis makes it likely that the number of children exposed to potentially unnecessary treatments will also increase. An informed and targeted approach to the diagnosis and management of the infections subsumed within the term ‘sepsis’ is required to optimize clinical outcomes. This requires cost-effective implementation of newly available validated rapid diagnostic tests. Therapy could be streamlined, exposing children only to those antimicrobial agents effective against the identified pathogen. Immunodiagnostics could also help guide immunomodulatory therapies [43,44]. Optimizing outcomes in pediatric sepsis requires rigorous research to identify those children that could benefit from rapid diagnostic testing and targeted antimicrobial treatment and those for whom this is unnecessary.

Competing interests

Dr. Randolph is on the Scientific Advisory Board for Ferring, Inc., Asahi Kasei Pharma, Inc. and Genentech, Inc. advising on the design of pediatric trials for sepsis agents.

The importance of identifying sepsis in the pre-hospital setting

Ron Daniels (Figure 6) and Tim Nutbeam (Figure 7)

Patients with sepsis are commonly transported to emergency departments by EMS [18,45,46]. These patients tend to have more severe sepsis and have a higher mortality than those who present by other methods [47]. As discussed in the previous sections, prompt identification and early treatment reduces the mortality and morbidity associated with sepsis. It has been demonstrated in the in-hospital setting that the earlier this identification and treatment delivery can occur the better a patient’s outcomes will be [48]. With an average pre-hospital care interval in excess of 45 minutes for patients with sepsis, early intervention should occur in the pre-hospital setting [16].

Sepsis has not been subject to the public health awareness campaigns that stroke and acute coronary syndromes have benefited from; as such, public awareness is low. A recent poll conducted by the UK Sepsis Trust identified that only 16% of the public were aware that sepsis was a time-critical condition [49]. These findings mirror similar surveys conducted in Germany and the USA.

Awareness amongst EMS professionals is also low, with less than 10% of pre-hospital providers having knowledge and skills sufficient to pass sepsis-focused scenarios in a recent survey [50]. This may, in part, be due to the lack of pre-hospital sepsis dispatch and clinical care protocols or guidelines in many regions [51,52]. Skills availability is also an issue; only about 50% of patients transported by an EMS system with severe sepsis will have a paramedic present [16]. The lack of a trained paramedic will impact at all stages of patient care, including awareness of sepsis (and its mimics), ability to screen a patient for the presence of sepsis, and ability to intervene (e.g., provide intravenous fluids).

There are a number of ways in which sepsis recognition can be improved in the pre-hospital setting. EMS practitioners should use a screening tool [51] to identify patients with sepsis. This should trigger the rapid delivery of effective protocolized care [53,54]. Lactate may be used to risk stratify patients effectively in the pre-hospital setting [17]. Unfortunately, few EMS systems have established sepsis care bundles, with the delivery of antibiotics outside of treatment protocols for suspected meningococcal sepsis being rare [51]. Even when protocols are available, EMS crews only successfully identify patients 21% of the time [47]. Delivery of intravenous fluid administration is achieved in less than half of cases (and intravenous cannulation in only one-third) with those who do receive fluid not demonstrating a decreased mortality [16,55].

Delivery to an emergency department by an EMS system is associated with improved in-hospital processes, demonstrated by a decreased time to antibiotics and an increased volume of intravenous fluid therapy [56], with these processes taking even less time when sepsis was identified in the pre-hospital environment [47,55]. Despite emergency department and in-hospital studies repeatedly demonstrating a decreased mortality with early care, early EMS identification and treatment have not consistently been associated with improved outcomes in this patient group [16,51,57] – placing a pre-hospital IV catheter and delivering fluids does, however, appear to be associated with a better outcome [18].

Improvement strategies are needed to increase early sepsis awareness in pre-hospital care at each step of the process. National and regional strategies should focus on the steps outlined in Box 1, and further details about clinical tools from the UK Sepsis Trust are given in Table 2.

Table 2 The Sepsis Six and Red Flag Sepsis, clinical tools from the UK Sepsis Trust

Competing interests

Ron Daniels and Tim Nutbeam both believe sepsis is an under-diagnosed, time critical condition that responds well to early judicious therapy: they have established a charity to improve sepsis care in the UK and further afield (the UK Sepsis Trust) – they have no financial conflicts of interest.



Emergency medical services


  1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10.

    Article  CAS  PubMed  Google Scholar 

  2. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–55.

    Article  CAS  PubMed  Google Scholar 

  3. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–77.

    Article  CAS  PubMed  Google Scholar 

  4. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165–228.

    Article  CAS  PubMed  Google Scholar 

  5. Rivers EP, Katranji M, Jaehne KA, Brown S, Abou Dagher G, Cannon C, et al. Early interventions in severe sepsis and septic shock: a review of the evidence one decade later. Minerva Anestesiol. 2012;78:712–24.

    CAS  PubMed  Google Scholar 

  6. Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42:1749–55.

    Article  CAS  PubMed  Google Scholar 

  7. Wang HE, Shapiro NI, Angus DC, Yealy DM. National estimates of severe sepsis in United States emergency departments. Crit Care Med. 2007;35:1928–36.

    Article  PubMed  Google Scholar 

  8. Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010;303:739–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. The ProCESS Investigators, Yealy DM, Kellum JA, Huang DT, et al. A randomized trial of protocol-based care for early septic shock. New Engl J Med. 2014;370:1683–1693.

  10. ARISE Investigators, ANZICS Clinical Trials Group, Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371:1496–506.

    Article  Google Scholar 

  11. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA. 2014;311:1308–16.

    Article  CAS  PubMed  Google Scholar 

  12. Reade MC, Huang DT, Bell D, Coats TJ, Cross AM, Moran JL, et al. Variability in management of early severe sepsis. Emerg Med J. 2010;27:110–5.

    Article  PubMed  Google Scholar 

  13. Yende S, Angus DC. Long-term outcomes from sepsis. Curr Infect Dis Rep. 2007;9:382–6.

    Article  PubMed  Google Scholar 

  14. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304:1787–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20:195–203.

    Article  PubMed  Google Scholar 

  16. Seymour CW, Rea TD, Kahn JM, Walkey AJ, Yealy DM, Angus DC. Severe sepsis in pre-hospital emergency care: analysis of incidence, care, and outcome. Am J Respir Crit Care Med. 2012;186:1264–71.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Guerra WF, Mayfield TR, Meyers MS, Clouatre AE, Riccio JC. Early detection and treatment of patients with severe sepsis by prehospital personnel. J Emerg Med. 2013;44:1116–25.

    Article  PubMed  Google Scholar 

  18. Seymour CW, Cooke CR, Heckbert SR, Spertus JA, Callaway CW, Martin-Gill C, et al. Prehospital intravenous access and fluid resuscitation in severe sepsis: an observational cohort study. Crit Care. 2014;18:533.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Rivers EP, Ahrens T. Improving outcomes for severe sepsis and septic shock: tools for early identification of at-risk patients and treatment protocol implementation. Crit Care Clin. 2008;24:S1–47.

    Article  CAS  PubMed  Google Scholar 

  20. Alsolamy S, Al Salamah M, Al Thagafi M, Al-Dorzi HM, Marini AM, Aljerian N, et al. Diagnostic accuracy of a screening electronic alert tool for severe sepsis and septic shock in the emergency department. BMC Med Inform Decis Mak. 2014;14:105.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Singer AJ, Taylor M, Domingo A, Ghazipura S, Khorasonchi A, Thode Jr HC, et al. Diagnostic characteristics of a clinical screening tool in combination with measuring bedside lactate level in emergency department patients with suspected sepsis. Acad Emerg Med. 2014;21:853–7.

    Article  PubMed  Google Scholar 

  22. Clinical Excellence Commission. Programs Sepsis Kills.

  23. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 2010;36:222–31.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Cross G, Bilgrami I, Eastwood G, Johnson P, Howden BP, Bellomo R, et al. The epidemiology of sepsis during rapid response team reviews in a teaching hospital. Anaesth Intensive Care. 2015;43:193–8.

    CAS  PubMed  Google Scholar 

  25. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:426–35.

    Article  CAS  PubMed  Google Scholar 

  26. Singer M. Biomarkers in sepsis. Curr Opin Pulm Med. 2013;19:305–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Acosta CD, Knight M, Lee HC, Kurinczuk JJ, Gould JB, Lyndon A. The continuum of maternal sepsis severity: incidence and risk factors in a population-based cohort study. PLoS One. 2013;8, e67175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Knight M, Kenyon S, Brocklehurst P, Neilson J, Shakespeare J, Kurinczuk J: on behalf of MBRRACE-UK. Saving Lives, Improving Mothers’ Care: lessons learned to inform future maternity care from the UK and Ireland confidential enquiries into maternal deaths and Morbidity 2009–2012. Oxford: National Perinatal Epidemiology Unit, University of Oxford; 2014.

  29. Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2:e323–33.

    Article  PubMed  Google Scholar 

  30. Arulkumaran N, Singer M. Puerperal sepsis. Best Pract Res Clin Obstet Gynaecol. 2013;27:893–902.

    Article  CAS  PubMed  Google Scholar 

  31. Acosta CD, Kurinczuk JJ, Lucas DN, Tuffnell DJ, Sellers S, Knight M, et al. Severe maternal sepsis in the UK, 2011–2012: a national case–control study. PLoS Med. 2014;11:e1001672.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Sriskandan S. Severe peripartum sepsis. J R Coll Physicians Edinb. 2011;41:339–46.

    Article  CAS  PubMed  Google Scholar 

  33. Institute for Healthcare Improvement. Severe Sepsis Bundles. Secondary Severe Sepsis Bundles. 2013.

  34. The UK Sepsis Trust. Clinical Toolkit.

  35. Randolph AG, McCulloh RJ. Pediatric sepsis: important considerations for diagnosing and managing severe infections in infants, children, and adolescents. Virulence. 2014;5:179–89.

    Article  PubMed  Google Scholar 

  36. Bahl R, Martines J, Ali N, Bhan MK, Carlo W, Chan KY, et al. Research priorities to reduce global mortality from newborn infections by 2015. Pediatr Infect Dis J. 2009;28:S43–8.

    Article  PubMed  Google Scholar 

  37. Goldstein B, Giroir B, Randolph A. International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6:2–8.

    Article  PubMed  Google Scholar 

  38. Miller MR, Niedner MF, Huskins WC, Colantuoni E, Yenokyan G, Moss M, et al. Reducing PICU central line-associated bloodstream infections: 3-year results. Pediatrics. 2011;128:e1077–83.

    Article  PubMed  Google Scholar 

  39. Paul R, Melendez E, Stack A, Capraro A, Monuteaux M, Neuman MI. Improving adherence to PALS septic shock guidelines. Pediatrics. 2014;133:e1358–66.

    Article  PubMed  Google Scholar 

  40. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372:835–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Randolph AG, Vaughn F, Sullivan R, Rubinson L, Thompson BT, Yoon G, et al. Critically ill children during the 2009–2010 influenza pandemic in the United States. Pediatrics. 2011;128:e1450–8.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011;364:2483–95.

    Article  CAS  PubMed  Google Scholar 

  43. Boomer JS, Green JM, Hotchkiss RS. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence. 2014;5:45–56.

    Article  PubMed  Google Scholar 

  44. Hall MW, Geyer SM, Guo CY, Panoskaltsis-Mortari A, Jouvet P, Ferdinands J, et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med. 2013;41:224–36.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Gray A, Ward K, Lees F, Dewar C, Dickie S, McGuffie C, et al. The epidemiology of adults with severe sepsis and septic shock in Scottish emergency departments. Emerg Med J. 2013;30:397–401.

    Article  PubMed  Google Scholar 

  46. Wang HE, Weaver MD, Shapiro NI, Yealy DM. Opportunities for emergency medical services care of sepsis. Resuscitation. 2010;81:193–7.

    Article  PubMed  Google Scholar 

  47. Studnek JR, Artho MR, Garner Jr CL, Jones AE. The impact of emergency medical services on the ED care of severe sepsis. Am J Emerg Med. 2012;30:51–6.

    Article  PubMed  Google Scholar 

  48. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38:1045–53.

    Article  PubMed  Google Scholar 

  49. UK Sepsis Trust. You Gov Poll - Public Awareness of Sepsis; 2014 Nov.

  50. Baez AA, Hanudel P, Perez MT, Giraldez EM, Wilcox SR. Prehospital Sepsis Project (PSP): knowledge and attitudes of United States advanced out-of-hospital care providers. Prehosp Disaster Med. 2013;28:104–6.

    Article  PubMed  Google Scholar 

  51. Herlitz J, Bang A, Wireklint-Sundstrom B, Axelsson C, Bremer A, Hagiwara M, et al. Suspicion and treatment of severe sepsis. An overview of the prehospital chain of care. Scand J Trauma Resusc Emerg Med. 2012;20:42.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Robson W, Nutbeam T, Daniels R. Sepsis: a need for prehospital intervention? Emerg Med J. 2009;26:535–8.

    Article  CAS  PubMed  Google Scholar 

  53. Daniels R, Nutbeam T, McNamara G, Galvin C. The Sepsis Six and the severe sepsis resuscitation bundle: a prospective observational cohort study. Emerg Med J. 2011;28:507–12.

    Article  PubMed  Google Scholar 

  54. Puskarich MA, Marchick MR, Kline JA, Steuerwald MT, Jones AE. One year mortality of patients treated with an emergency department based early goal directed therapy protocol for severe sepsis and septic shock: a before and after study. Crit Care. 2009;13:R167.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Seymour CW, Cooke CR, Mikkelsen ME, Hylton J, Rea TD, Goss CH, et al. Out-of-hospital fluid in severe sepsis: effect on early resuscitation in the emergency department. Prehosp Emerg Care. 2010;14:145–52.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Band RA, Gaieski DF, Hylton JH, Shofer FS, Goyal M, Meisel ZF. Arriving by emergency medical services improves time to treatment endpoints for patients with severe sepsis or septic shock. Acad Emerg Med. 2011;18:934–40.

    Article  PubMed  Google Scholar 

  57. Femling J, Weiss S, Hauswald E, Tarby D. EMS patients and walk-in patients presenting with severe sepsis: differences in management and outcome. South Med J. 2014;107:751–6.

    Article  PubMed  Google Scholar 

  58. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206–17.

    Article  CAS  PubMed  Google Scholar 

  59. Wu Y, Wang F, Fan X, Bao R, Bo L, Li J, et al. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. Crit Care. 2012;16:R229.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Donald M Yealy.

Additional information

All correspondence should be made to the journal editorial office:

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yealy, D.M., Huang, D.T., Delaney, A. et al. Recognizing and managing sepsis: what needs to be done?. BMC Med 13, 98 (2015).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: